新诊断癫痫患者经传统与新型抗癫痫药物治疗的结局:30年纵向队列研究
该研究在苏格兰格拉斯哥西部医院癫痫单元开展纵向观察性队列研究,纳入1982年7月1日至2012年10月31日期间新接受抗癫痫药物治疗的1795例癫痫患者,随访至少2年。结果显示,尽管过去20年有多种新型抗癫痫药上市,新诊断癫痫的整体治疗结局并未改善,多数患者通过第一种或第二种药物实现控制,后续药物方案获得无发作的概率显著降低,超过三分之一患者癫痫仍未控制。
要点
- 尽管新型抗癫痫药增多,新诊断癫痫的整体治疗结局未改善。
- 多数实现无发作的患者通过第一种或第二种抗癫痫药方案达到控制。
- 第一种药物失败后,后续每种药物方案获得无发作的概率显著降低。
核心结论
- 尽管有多种不同作用机制的新型抗癫痫药可用,新诊断癫痫的整体结局并未改善。
- 大多数获得控制的患者通过第一种或第二种抗癫痫药实现无发作。
- 每尝试一种后续抗癫痫药方案,获得无发作的概率显著降低。
- 超过三分之一患者癫痫仍未得到控制。
研究设计与样本
- 纵向观察性队列研究,在苏格兰格拉斯哥西部医院癫痫单元开展。
- 纳入1982年7月1日至2012年10月31日期间新接受抗癫痫药物治疗的1795例癫痫患者。
- 所有患者随访至少2年(至2014年10月31日)或直至死亡,以较早者为准。
- 数据分析于2015年3月至2016年5月完成。
主要发现
- 1795例患者中964例(53.7%)为男性,中位年龄33岁(范围9-93岁)。
- 研究结束时1144例(63.7%)在过去1年或更长时间无发作。
- 实现1年无发作的患者中,993例(86.8%)接受单药治疗,1028例(89.9%)通过第一种或第二种抗癫痫药方案实现控制。
- 全部患者中906例(50.5%)使用初始抗癫痫药保持1年或更长时间无发作。
- 初始抗癫痫药失败后,第二种和第三种方案分别额外提供11.6%和4.4%的无发作可能性;仅2.12%的患者通过后续抗癫痫药达到最佳发作控制。
临床怎么用
- 新诊断癫痫应优先优化第一种抗癫痫药方案,因其对多数患者可实现长期无发作。
- 第一种药物失败后,应意识到后续方案获得无发作的概率显著降低,需更积极评估和个体化治疗。
- 超过三分之一患者癫痫未控制,提示需关注难治性癫痫的早期识别与综合管理。
局限性
- 研究为单中心观察性队列,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A study published in 2000 showed that more than one-third of adults with epilepsy have inadequate control of seizures with antiepileptic drugs (AEDs). This study evaluates overall treatment outcomes in light of the introduction of more than 1 dozen new AEDs in the past 2 decades. OBJECTIVE: To assess long-term treatment outcome in patients with newly diagnosed and treated epilepsy. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal observational cohort study was conducted at the Epilepsy Unit of the Western Infirmary in Glasgow, Scotland. A total of 1795 individuals who were newly treated for epilepsy with AEDs between July 1, 1982, and October 31, 2012, were included in this analysis. All patients were followed up for a minimum of 2 years (until October 31, 2014) or until death, whichever came sooner. Data analysis was completed between March 2015 and May 2016. EXPOSURES: Treatment with antiepileptic drugs for patients newly diagnosed with epilepsy. MAIN OUTCOMES AND MEASURES: Seizure control was assessed at the end of the study period. Probability of achieving 1-year seizure freedom was estimated for each AED regimen prescribed. Multivariable models assessed the associations between risk factors and AED treatment outcome after adjustments were made for demographic and clinical characteristics. RESULTS: Of the 1795 included patients, 964 (53.7%) were male; the median age was 33 years (range, 9-93 years). At the end of the study period, 1144 patients (63.7%) had been seizure free for the previous year or longer. Among those achieving 1-year seizure freedom, 993 (86.8%) were taking monotherapy and 1028 (89.9%) had achieved seizure control with the first or second AED regimens. Of the total patient pool, 906 (50.5%) remained seizure free for 1 year or longer with the initial AED. If this AED failed, the second and third regimens provided an additional 11.6% and 4.4% likelihoods of seizure freedom, respectively. Only 2.12% of patients attained optimal seizure control with subsequent AEDs. Epilepsy that was not successfully controlled with the first AED had 1.73 times greater odds of not responding to treatment for each subsequent medication regimen (odds ratio, 1.73; 95% CI, 1.56-1.91; P < .001). CONCLUSIONS AND RELEVANCE: Despite the availability of many new AEDs with differing mechanisms of action, overall outcomes in newly diagnosed epilepsy have not improved. Most patients who attain control do so with the first or second AED. The probability of achieving seizure freedom diminishes substantially with each subsequent AED regimen tried. More than one-third of patients experience epilepsy that remains uncontrolled.
引用
- Chen Z, Brodie MJ, Liew D, et al. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurol. 2018. PMID: 29279892. doi:10.1001/jamaneurol.2017.3949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。